Definition
GABA (gamma-aminobutyric acid) is the most abundant inhibitory neurotransmitter in the central nervous system. It reduces neuronal excitability by binding to GABA receptors on the surface of neurons, making those neurons less likely to fire. GABA works in a complementary relationship with glutamate, the brain's primary excitatory neurotransmitter. Together, they maintain the delicate balance between neural excitation and inhibition that underlies healthy brain function.
How GABA Works
GABA is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD). Once released into the synapse, GABA binds to two main receptor types. GABA-A receptors are ligand-gated ion channels that allow chloride ions to flow into the neuron, rapidly hyperpolarizing it and reducing its ability to fire. GABA-B receptors are G-protein-coupled receptors that produce slower, longer-lasting inhibitory effects through intracellular signaling cascades.
Approximately 20 to 25 percent of all neurons in the brain are GABAergic interneurons — cells that release GABA to regulate the activity of surrounding neurons. These interneurons act as gatekeepers, preventing excessive excitation and maintaining orderly neural signaling. Without adequate GABA function, neural circuits can become overactive, contributing to conditions such as anxiety, seizures, and insomnia.
Relationship to Ketamine
Ketamine's interaction with the GABAergic system is central to understanding its antidepressant mechanism. The prevailing disinhibition hypothesis holds that ketamine preferentially blocks NMDA receptors on GABAergic interneurons. Because these interneurons normally suppress the activity of excitatory pyramidal neurons, blocking their NMDA receptors effectively removes the brake, causing a transient surge of glutamate release in the prefrontal cortex and hippocampus.
This glutamate burst activates AMPA receptors on downstream neurons, triggering a cascade of events that includes BDNF release, mTOR pathway activation, and rapid synaptogenesis. In essence, ketamine's antidepressant effects arise not from directly enhancing GABA activity but from temporarily suppressing GABA-mediated inhibition to unleash a restorative wave of excitatory signaling and neuroplasticity.
GABA and Depression
Research has consistently found that individuals with major depressive disorder have reduced GABA levels in the brain, particularly in the prefrontal cortex and occipital cortex. Magnetic resonance spectroscopy (MRS) studies have measured GABA concentrations in depressed patients and found deficits of up to 50 percent compared to healthy controls. These reductions correlate with symptom severity and tend to normalize with successful treatment.
The relationship between GABA deficits and depression is complex. Low GABA may contribute to the neural circuit dysfunction that characterizes depression, while the chronic stress that drives depression may itself reduce GABA synthesis and receptor expression. Ketamine's ability to work through — and partly around — the impaired GABAergic system may explain why it is effective even in patients who have not responded to other treatments.
GABA in Pharmacology
Many common psychiatric medications target the GABA system directly. Benzodiazepines (such as lorazepam and diazepam) enhance GABA-A receptor function, producing anxiolytic, sedative, and anticonvulsant effects. Barbiturates similarly potentiate GABA-A receptors at higher doses. Some anticonvulsants, including gabapentin and vigabatrin, work by increasing GABA availability in the synapse.
Ketamine is distinct from these drugs because it does not directly bind to GABA receptors. Instead, its effects on the GABAergic system are indirect, mediated through NMDA receptor blockade on GABA-releasing interneurons. This indirect mechanism produces fundamentally different therapeutic outcomes — rapid neuroplasticity rather than sedation — and carries a different side effect profile.
References
- Reduced GABA Levels in Major Depressive Disorder — Sanacora et al. (1999), Archives of General Psychiatry. Early evidence of GABA deficits in depression.
- GABAergic Deficits in Depression: A Review — Luscher et al. (2011), Molecular Psychiatry. Comprehensive review of GABA's role in depressive disorders.
- Disinhibition Model of Ketamine Action — NIH resource on the GABA interneuron disinhibition hypothesis.
Share